NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1508.70 11.10 (0.74%)

881.4K NSE+BSE Volume

NSE 03 Jul, 2025 3:31 PM (IST)

121,865.4

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

14 May 2025

1508.70

0.74%

Cipla (CIPLA IN) Q4FY25 Result Update In-line EBITDA;...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q4FY25 EBITDA (Rs15.4bn; 22.8% OPM) was in line with our estimates. While Q4 is seasonally weak quarter; margins at 23% were above our estimate. Despite delay in new launches and supply issues of gLanreotide; Cipla managed to deliver strong profitability/margins in H2FY25. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla Ltd.

11 Apr 2025

1508.70

0.74%

Cipla (CIPLA IN) Event Update Gets approval for...

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla Ltd.

29 Jan 2025

1508.70

0.74%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We maintain our BUY recommendation with a target price of Rs 1,700/share.

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla Ltd.

29 Jan 2025

1508.70

0.74%

CIPLA LTD.

Buy: Cipla Ltd.

Prabhudas Lilladhar

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla Ltd.

28 Jan 2025

1508.70

0.74%

3Q results beat estimates; yet to scale up Lanreotide supply

Neutral: Cipla Ltd.

Recommendation Target

Motilal Oswal

CIPLA delivered better-than-expected 3QFY25 earnings. While revenue was in line, EBITDA/adj. PAT beat our estimates, aided by a better product mix and lower R&D spending.

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla Ltd.

17 Jan 2025

1508.70

0.74%

Empowering health, Enriching Lives

Accumulate: Cipla Ltd.

Asit C Mehta Investment Interrmediates

Cipla's "Future Fit" strategy outlines ambitious growth objectives, including becoming India’s 2nd largest pharmaceutical company, leading South Africa’s prescription and OTC markets, ranking 2nd in U.S. respiratory generics, and doubling international revenue.

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla Ltd.

04 Dec 2024, 12:00AM

1508.70

0.74%

CIPLA LTD

Buy: Cipla Ltd.

Target

Geojit BNP Paribas

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

28 Nov 2024

1508.70

0.74%

CIPLA LTD.

Buy: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

04 Nov 2024, 12:00AM

1508.70

0.74%

New launches and strong market expansion will drive top-line growth

Accumulate: Cipla Ltd.

Target

KRChoksey

Cipla’s revenue was largely in-line with our estimates (-2.0%), EBITDA was in-line (+0.2%) and Adj. PAT beat our estimates (+3.4%) due to lower-than-expected finance costs and higher-than-expected other income.